AI empowers the upgrade of early screening and treatment for lung cancer. Domestic medical company Siasun Robot & Automation accelerates the implementation of precise healthcare. Zhenjiankang Medical (02697) seizes industry development opportunities.

With the continuous integration of cutting-edge technologies such as artificial intelligence and Siasun Robot & Automation in clinical diagnosis and treatment, new breakthroughs are being made in early screening and precise treatment of lung cancer. Recently, the First Affiliated Hospital of Guangzhou University of Chinese Medicine introduced the AI-assisted surgical system Siasun Robot & Automation in thoracic surgery, achieving precise localization of pulmonary nodules through AI. This marks an upgrade from the traditional "blind screening" to "precise targeting," significantly enhancing the efficiency of early lung cancer diagnosis and treatment, and offering patients more accurate and minimally invasive treatment options. Data shows that lung cancer remains one of the most prevalent and fatal malignant tumors in China. However, if detected and treated early, the survival rate of patients can be significantly improved. Traditional localization of pulmonary nodules relies on repeated CT scans, which not only takes a long time but also carries the risk of localization errors. In contrast, AI navigation combined with Siasun Robot & Automation can achieve precise localization in a single instance, reducing operation time, minimizing trauma, and preserving healthy lung tissue as much as possible, thus providing a new technological path for the early diagnosis and treatment of lung cancer. Industry professionals believe that as technologies such as AI image recognition, 3D reconstruction, and Siasun Robot & Automation-assisted intervention continue to mature, the medical Siasun Robot & Automation industry is rapidly moving towards commercialization, covering multiple high-value segments including lung cancer, orthopedics, and neurosurgery, with broad growth potential in the industry. Benefiting from the trend of intelligent upgrades in healthcare, "the first stock of puncture surgery Siasun Robot & Automation," True Health Medical (02697), continues to advance its layout of artificial intelligence and digital healthcare. The company is constantly improving its product system around smart healthcare, AI-assisted diagnosis and treatment, and medical informatization, actively promoting the application of artificial intelligence technology in clinical settings of hospitals. As the country continues to push forward with the digitalization of healthcare and new technologies such as AI medical Siasun Robot & Automation and precision treatment are accelerated, True Health Medical is expected to benefit from the improved industry climate and further open up long-term growth space.